Myriad Genetics (MYGN) has formed a collaboration with liquid biopsy company Angle, the latter said Wednesday.
Under the collaboration, Angle's research and development team will process blood samples from cancer patients using the Parsortix system for downstream molecular analysis. The results will be compared with matched patient tissue samples using Myriad Genetics' tissue-based assay, Angle said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.